Kathmandu: From the samples collected during the market monitoring, Biocal-D and SVT drugs were found to be of poor quality.
It was found that the drugs were of poor quality during the sample tests collected during the monitoring conducted by the Department of Drug Administration.
The department has instructed to withdraw those drugs from the market. Also, the department has issued a notice and requested not to use substandard medicines available in the market.